Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised GeneraLife in connection with its acquisition of Livio Group
Mandate

Vinge has advised GeneraLife in connection with its acquisition of Livio Group

September 13, 2022 EU, Competition and Regulatory M&A Employment and Benefits IT, Telecommunications and Outsourcing Real Estate and Construction Banking and Finance Restructuring and Insolvency

Vinge has advised GeneraLife, one of Europe's largest fertility clinic groups and owned by KKR, in connection with its acquisition of Livio Group.

Livio is the largest fertility clinics group in the Nordics, present with 9 clinics in Sweden, Norway and Iceland. The acquisition also encompasses the Livio's own gamete bank, Livio Egg and Sperm Bank, with a sales hub in Denmark.

Vinge's team consisted of responsible partner Matthias Pannier and associates, Samra Baytar, Stina Bengtsson, Olivia Belding, Elias Bohlin (M&A), Trine Osen Bergqvist, Johan Wahlbom, Jakob Jeanrond, Victoria Fredén, Alva Chambert (Antitrust), Christoffer Nordin, Mika Jordan (Regulatory & Agreements), Rebecka Målquist (IP), Frida Ställborn, Karolina Cohrs (Real Estate), Calle Tengwall Pagels (Banking & Finance), Gustav Lindgren (Employment), Karolina Fuhrman (IT & GDPR) and Jessica Henning (Project Assistance).

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

 Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

 Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025